接受帕博西利联合氟维司群治疗的激素受体阳性/HER2阴性转移性乳腺癌患者的血清胸苷激酶活性
PYTHIA是一项II期单臂多中心试验,纳入124例内分泌抵抗的激素受体阳性/HER2阴性转移性乳腺癌绝经后女性,前瞻性分析血清胸苷激酶活性(sTKa)与无进展生存期的关联。结果显示,治疗前sTKa与临床特征无关、与组织Ki-67中度相关;帕博西利联合氟维司群在D15显著抑制sTKa,83%患者低于检测下限,D28时60%患者出现反弹;各时间点较高sTKa均与较短无进展生存期相关(均p<0.001),D15效应最强。
要点
- 治疗前sTKa与临床特征无关,与组织Ki-67中度相关。
- 帕博西利联合氟维司群在D15显著抑制sTKa,83%患者低于检测下限。
- 各时间点较高sTKa均与较短无进展生存期相关(均p<0.001),D15效应最强。
核心结论
- sTKa是接受帕博西利治疗患者的独立预后生物标志物。
- 治疗前高sTKa及其治疗中不完全抑制可能识别预后较差和原发耐药的患者。
- 作者认为这需要在前瞻性对照试验中验证。
研究设计与样本
- PYTHIA是一项II期、单臂、多中心试验,纳入124例内分泌抵抗的激素受体阳性/HER2阴性转移性乳腺癌绝经后女性。
- 血清样本采集时间:治疗前(n=122)、第1周期第15天(D15;n=108)、第2周期开始前帕博西利停药一周期间(D28;n=108)及治疗结束时(n=76)。
- sTKa采用Divitum®集中检测,该法为改良ELISA,检测下限为20 Divitum Units(Du)/L。
- 主要研究终点为无进展生存期,评估其与治疗前和治疗中sTKa的关联。
- 共分析122例女性的数据。
主要发现
- 治疗前sTKa与临床特征无关,与组织Ki-67中度相关。
- 帕博西利联合氟维司群在D15显著抑制sTKa,83%患者记录的水平低于检测下限。
- D28时60%患者sTKa出现反弹。
- 各时间点较高sTKa均与较短无进展生存期相关(均p<0.001),D15效应最强。
局限性
- 原文结论指出需在前瞻性对照试验中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biomarkers for cyclin-dependent kinase 4/6 inhibitors, such as palbociclib, for patients with hormone receptor-positive/HER2-negative metastatic breast cancer are lacking. Thymidine kinase is a proliferation marker downstream of the cyclin-dependent kinase 4/6 pathway. We prospectively investigated the prognostic role of serum thymidine kinase activity (sTKa), in patients treated with Palbociclib + fulvestrant. PATIENTS AND METHODS: PYTHIA was a phase II, single-arm, multicentre, trial that enrolled 124 post-menopausal women with endocrine-resistant hormone receptor-positive/HER2-negative metastatic breast cancer. Serum samples were collected pre-treatment (pre-trt; n = 122), at day 15 of cycle 1 (D15; n = 108), during the one week-off palbociclib before initiating cycle 2 (D28; n = 108) and at end of treatment (n = 76). sTKa was determined centrally using Divitum®, a refined ELISA-based assay with a limit of detection of 20 Divitum Units (Du)/L. The primary study endpoint was progression-free survival, assessed for its association with pre- and on-treatment sTKa. RESULTS: Data from 122 women were analysed. Pre-treatment sTKa was not associated with clinical characteristics and moderately correlated with tissue Ki-67. Palbociclib + fulvestrant markedly suppressed sTKa levels at D15, with 83% of patients recording levels below limit of detection. At D28, sTKa showed a rebound in 60% of patients. At each timepoint, higher sTKa was associated with shorter progression-free survival (each p < 0.001), with the strongest effect at D15. CONCLUSIONS: STKa is an independent prognostic biomarker in patients treated with palbociclib. High pre-treatment sTKa and its incomplete suppression during treatment may identify patients with poorer prognosis and primary resistance. This warrants validation in prospective comparative trials. CLINICALTRIALS. GOV IDENTIFIER: NCT02536742; EudraCT 2014-005387-15.
引用
- Malorni L, Tyekucheva S, Hilbers FS, et al. Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. Eur J Cancer. 2022. PMID: 35172272. doi:10.1016/j.ejca.2021.12.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。